168 related articles for article (PubMed ID: 31115638)
1. Treatment of brain metastases of castration-resistant prostate cancer with
Sathekge MM; Bruchertseifer F; Lawal IO; Vorster M; Knoesen O; Lengana T; Boshomane TG; Mokoala KK; Morgenstern A
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1756-1757. PubMed ID: 31115638
[No Abstract] [Full Text] [Related]
2. Successful Treatment of Hepatic Metastases of Hormone Refractory Prostate Cancer Using Radioligand Therapy With 177Lu-PSMA-617.
Wei X; Schlenkhoff C; Sopora C; Essler M; Ahmadzadehfar H
Clin Nucl Med; 2016 Nov; 41(11):894-895. PubMed ID: 27607162
[TBL] [Abstract][Full Text] [Related]
3. Exceptional 4-year response to
Gafita A; Wang H; Tauber R; D'Alessandria C; Weber WA; Eiber M
Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2212-2213. PubMed ID: 31273434
[No Abstract] [Full Text] [Related]
4. Combination of 177Lu-PSMA-617 and External Radiotherapy for the Treatment of Cerebral Metastases in Patients With Castration-Resistant Metastatic Prostate Cancer.
Wei X; Schlenkhoff C; Schwarz B; Essler M; Ahmadzadehfar H
Clin Nucl Med; 2017 Sep; 42(9):704-706. PubMed ID: 28719450
[TBL] [Abstract][Full Text] [Related]
5. Excellent Response to Lower Dose of 177Lu-PSMA-617 in a Metastatic Castration-Resistant Prostate Cancer Patient With a Transplanted Kidney.
Norouzi G; Aghdam RA; Hashemifard H; Pirayesh E
Clin Nucl Med; 2019 Jun; 44(6):483-484. PubMed ID: 30829871
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Multiple Bone Metastases of Castration-Resistant Prostate Cancer With 225 Ac-PSMA-617.
Yang H; Zhang Y; Su D; Zhang Y; Chen Y
Clin Nucl Med; 2023 Dec; 48(12):1078-1081. PubMed ID: 37796187
[TBL] [Abstract][Full Text] [Related]
7. Excellent Response to 177Lu-PSMA-617 Radioligand Therapy in a Patient With Advanced Metastatic Castration Resistant Prostate Cancer Evaluated by 68Ga-PSMA PET/CT.
Roll W; Bode A; Weckesser M; Bögemann M; Rahbar K
Clin Nucl Med; 2017 Feb; 42(2):152-153. PubMed ID: 27922871
[TBL] [Abstract][Full Text] [Related]
8.
Sathekge M; Knoesen O; Meckel M; Modiselle M; Vorster M; Marx S
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):1099-1100. PubMed ID: 28255795
[No Abstract] [Full Text] [Related]
9. (18)F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617.
Giesel FL; Cardinale J; Schäfer M; Neels O; Benešová M; Mier W; Haberkorn U; Kopka K; Kratochwil C
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1929-30. PubMed ID: 27342416
[No Abstract] [Full Text] [Related]
10.
Rahbar K; Bögemann M; Ahmadzadehfar H
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):166-167. PubMed ID: 27699719
[No Abstract] [Full Text] [Related]
11. Influence of short-term dexamethasone on the efficacy of
Derlin T; Sommerlath Sohns JM; Schmuck S; Henkenberens C; von Klot CAJ; Ross TL; Bengel FM
Prostate; 2020 May; 80(8):619-631. PubMed ID: 32187729
[TBL] [Abstract][Full Text] [Related]
12. PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival.
Rahbar K; Boegemann M; Yordanova A; Eveslage M; Schäfers M; Essler M; Ahmadzadehfar H
Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):12-19. PubMed ID: 29026946
[TBL] [Abstract][Full Text] [Related]
13. A Walk with Lu-177 PSMA: How Close we Have Reached from Bench to Bedside?
Gupta M; Karthikeyan G; Choudhury PS; Babu Koyyala VP; Sharma M; Jain P; Talwar V; Singh A; Rawal S
Cancer Invest; 2020 Sep; 38(8-9):486-492. PubMed ID: 32804008
[TBL] [Abstract][Full Text] [Related]
14.
Rahbar K; Ahmadzadehfar H; Boegemann M
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):513-514. PubMed ID: 29164300
[No Abstract] [Full Text] [Related]
15. The value of tumor markers in men with metastatic prostate cancer undergoing [
Yordanova A; Linden P; Hauser S; Feldmann G; Brossart P; Fimmers R; Essler M; Holdenrieder S; Ahmadzadehfar H
Prostate; 2020 Jan; 80(1):17-27. PubMed ID: 31579967
[TBL] [Abstract][Full Text] [Related]
16. Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for
Thang SP; Violet J; Sandhu S; Iravani A; Akhurst T; Kong G; Ravi Kumar A; Murphy DG; Williams SG; Hicks RJ; Hofman MS
Eur Urol Oncol; 2019 Nov; 2(6):670-676. PubMed ID: 31412006
[TBL] [Abstract][Full Text] [Related]
17. Reply to Rahbar K et al.
Yadav MP; Ballal S; Tripathi M; Bal C
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):168-169. PubMed ID: 27695908
[No Abstract] [Full Text] [Related]
18. Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with
Kratochwil C; Bruchertseifer F; Rathke H; Bronzel M; Apostolidis C; Weichert W; Haberkorn U; Giesel FL; Morgenstern A
J Nucl Med; 2017 Oct; 58(10):1624-1631. PubMed ID: 28408529
[TBL] [Abstract][Full Text] [Related]
19. Long-term Survival and Excellent Response to Repeated 177Lu-Prostate-Specific Membrane Antigen 617 Radioligand Therapy in a Patient With Advanced Metastatic Castration-Resistant Prostate Cancer.
Roll W; Bräuer A; Weckesser M; Bögemann M; Rahbar K
Clin Nucl Med; 2018 Oct; 43(10):755-756. PubMed ID: 30036254
[TBL] [Abstract][Full Text] [Related]
20. The Imperative for Comparative Studies in Nuclear Medicine: Elevating
Rahbar K; Boegemann M
J Nucl Med; 2024 Feb; 65(2):224-225. PubMed ID: 38176720
[No Abstract] [Full Text] [Related]
[Next] [New Search]
